Effect of Elagolix in comparison to Dienogest in the treatment of symptomatic adenomyosis

Adenomyosis, a benign gynecological disorder, is diagnosed with increasing frequency in infertile patients since women delay their first pregnancy. Common symptoms of adenomyosis are dysmenorrhea and heavy menstrual bleeding (HMB), resulting in poor quality of life. Elagolix, the oral GnRH antagonist, acts by reducing the occurrence of ectopic endometrial implants in the myometrium. It diminishes uterine volume, reduces dysmenorrhea and heavy bleeding, and improves fertility outcomes. Dienogest, a synthetic oral progestin highly selective for progesterone receptors, reduces the painful symptoms in women with adenomyosis. The aim or this study was to compare the effect of Elagolix with Dienogest in the treatment of symptomatic adenomyosis.

This randomized controlled trial was conducted in the department of reproductive endocrinology and infertility, Bangabandhu Sheikh Mujib medical university (BSMMU), Dhaka, from January 2024 to December 2024. A total of 58 participants with symptomatic adenomyosis were randomly assigned to 2 groups (n=29). Each group received either Elagolix (200 mg) or Dienogest (2 mg) once daily for 3 months.

Compared between the two groups, post-treatment mean changes of VAS score (6.25±1.83 vs 4.84±1.56), hemoglobin (-1.21±0.97 vs-0.20±0.56), and median uterine volume (5.1 vs 1.2) were significantly higher in the Elagolix group than the Dienogest group. HMB was also significantly reduced (3.7% vs 23.1%) in the Elagolix than the Dienogest group after 3 months of treatment.

Elagolix significantly reduced VAS score, HMB, and uterine volume in symptomatic adenomyosis compared to Dienogest. Metrics

Osuga, Y., Fujimoto-Okabe, H. and Hagino, A., Evaluation of the efficacy and safety of Dienogest in the treatment of painful symptoms in patients with adenomyosis: a randomized, double-blind, multicenter, placebo-controlled study. Fertil Steril. 2017;108(4):673-8. DOI: https://doi.org/10.1016/j.fertnstert.2017.07.021 Donnez J, Stratopoulou CA, Dolmans MM. Uterine Adenomyosis: From Disease Pathogenesis to a New Medical Approach Using GnRH Antagonists. Int J Environm Res Publ Heal. 2021;18(19):9941. DOI: https://doi.org/10.3390/ijerph18199941 Abu Hashim H, Elaraby S, Fouda AA, Rakhawy ME. The prevalence of adenomyosis in an infertile population: a cross-sectional study. Reproduct Biomed. 2020;40(6):842-50. DOI: https://doi.org/10.1016/j.rbmo.2020.02.011 Puente JM, Fabris A, Patel J, Patel A, Cerrillo M, Requena A, Garcia-Velasco JA. Adenomyosis in infertile women: prevalence and the role of 3D ultrasound as a marker of severity of the disease. Reproduct Biol Endocrinol. 2016;14(1):60. DOI: https://doi.org/10.1186/s12958-016-0185-6 Stratopoulou CA, Donnez J, Dolmans MM. Conservative management of uterine adenomyosis: medical vs. surgical approach. J Clin Med. 2021;10(21):4878. DOI: https://doi.org/10.3390/jcm10214878 Song SY, Lee SY, Kim HY, Park DB, Kim DE, Lee KH, et al. Long-term efficacy and feasibility of levonorgestrel-releasing intrauterine device use in patients with adenomyosis. Medicine. 2020;99(22):e20421. DOI: https://doi.org/10.1097/MD.0000000000020421 Rapkin AJ, Nathan L. Pelvic Pain and dysmenorrhea, in Berek and Novak’s Gynecology. In: J.S. Berek., editor. Lippincott Williams and Wilkins: Philadelphia. 2012;481-2. Cunningham RK, Horrow MM, Smith RJ, Springer J. Adenomyosis: A Sonographic Diagnosis. Radiographics: a review publication of the Radiological Society of North America, Inc. 2018;38(5):1576-89. DOI: https://doi.org/10.1148/rg.2018180080 Donnez J, Donnez O, Dolmans MM. Introduction: Uterine adenomyosis, is another enigmatic disease of our time. Fertil Steril 2018;109(3):369-70. DOI: https://doi.org/10.1016/j.fertnstert.2018.01.035 Bulun SE, Yildiz S, Adli M, Chakravarti D, Parker JB, Milad M, et al. Endometriosis and adenomyosis: shared pathophysiology. Fertil Steril. 2023;119(5):746-50. DOI: https://doi.org/10.1016/j.fertnstert.2023.03.006 Li Q, Ding Y, Zhang XY, Feng WW, Hua KQ. Drug therapy for adenomyosis: a prospective, nonrandomized, parallel-controlled study. J Int Med Res. 2018;46(5):1855-65. DOI: https://doi.org/10.1177/0300060517752997 Horton J, Sterrenburg M, Lane S, Maheshwari A, Li TC, Cheong Y. Reproductive, obstetric, and perinatal outcomes of women with adenomyosis and endometriosis: a systematic review and meta-analysis. Hum Reproduct. 2019;25(5):592-632. DOI: https://doi.org/10.1093/humupd/dmz012 Park DS, Kim ML, Song T, Yun BS, Kim MK, Jun HS, et al. Clinical experiences of the levonorgestrel-releasing intrauterine system in patients with large symptomatic adenomyosis. Taiw J Obstetr Gynecol. 2015;54(4):412-5. DOI: https://doi.org/10.1016/j.tjog.2014.05.009 Kadam N, Khalid S, Jayaprakasan K. How Reproducible Are the Ultrasound Features of Adenomyosis Defined by the Revised MUSA Consensus? J Clin Med. 2025;14(2):456. DOI: https://doi.org/10.3390/jcm14020456 Tsui KH, Lee FK, Seow KM, Chang WC, Wang JW, Chen SU, et al. Conservative surgical treatment of adenomyosis to improve fertility: controversial values, indications, complications, and pregnancy outcomes. Taiw J Obstetr Gynecol. 2015;54(6):635-40. DOI: https://doi.org/10.1016/j.tjog.2015.05.003 Liu L, Wang T, Lei B. Image-guided thermal ablation in the management of symptomatic adenomyosis: a systematic review and meta-analysis. Int J Hyperth. 2021;38(1):948-62. DOI: https://doi.org/10.1080/02656736.2021.1939443 Hirata T, Izumi G, Takamura M, Saito A, Nakazawa A, Harada M, et al. Efficacy of Dienogest in the treatment of symptomatic adenomyosis: a pilot study. Gynecol Endocrinol. 2014;30(10):726-9. DOI: https://doi.org/10.3109/09513590.2014.926882 Diamond MP, Carr B, Dmowski WP, Koltun W, O'Brien C, Jiang P, et al. Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study. Reproductive sciences (Thousand Oaks, Calif.). 2014;21(3):363-71. DOI: https://doi.org/10.1177/1933719113497292 Taylor HS, Bedaiwy MA, Lukes AS, Chwalisz K, Owens C, Bradley L. Efficacy and safety of Elagolix in a subgroup of women with uterine fibroids and adenomyosis: results from a phase 2 trial. Fertil Steril. 2018;110(4):e61. DOI: https://doi.org/10.1016/j.fertnstert.2018.07.186 Neriishi K, Hirata T, Fukuda S, Izumi G, Nakazawa A, Yamamoto N, et al. Long‐term Dienogest administration in patients with symptomatic adenomyosis. J Obstetr Gynaecol Res. 2018;44(8):1439-44. DOI: https://doi.org/10.1111/jog.13674 Yamanaka K, Washio K, Uchida A, Sasagawa Y, Nishimoto M, Yamasaki Y, et al. Rapid reduction of adenomyosis coexisting with leiomyoma volume during treatment with Relugolix. Gynecolog Endocrinol. 2023;39(1):2237121. DOI: https://doi.org/10.1080/09513590.2023.2237121 Muneyyirci-Delale O, Archer DF, Owens CD, Barnhart KT, Bradley LD, Feinberg E, et al. Efficacy and safety of Elagolix with add-back therapy in women with uterine fibroids and coexisting adenomyosis. F S Rep. 2021;2(3):338-46. DOI: https://doi.org/10.1016/j.xfre.2021.05.004 Ali MK, Hussein RS, Abdallah KS, Mohamed AA. The use of Dienogest in treatment of symptomatic adenomyosis: a systematic review and meta-analysis. J Gynecol Obstetr Human Reproduct. 2024;102795. DOI: https://doi.org/10.1016/j.jogoh.2024.102795 Yang S, Liu Y, Wen J, Sun Y, Ren F. Clinical Efficacy of Dienogest versus Levonorgestrel-Releasing Intrauterine System for Adenomyosis. Evidence-Based Complement Alternat Med. 2022;1995472:6. DOI: https://doi.org/10.1155/2022/1995472 Xu Y, Li L, Yang G. Clinical Efficacy of Dienogest and Levonorgestrel-Releasing Intrauterine System in the Treatment of Adenomyosis. J Clin Nursing Res. 2022;6(5):141-5. DOI: https://doi.org/10.26689/jcnr.v6i5.4213